News & Investors

Want to stay updated? Subscribe to our newsletters. For free.

Have questions? Our live support would be happy to help you.

Category: Insider Information

Epigenomics AG: Notice of Loss pursuant to § 92 par. 1 AktG

PDF 76 KB   Not for distribution in the United States Berlin, Germany – The Executive Board of Epigenomics AG (ISIN: E000A1K0516) notifies that during the preparation of the annual financial statements pursuant to German GAAP (HGB) accounting, according to its best judgment a cumulative loss of more than half of the nominal share capital […]

Read more

Ad hoc: Epigenomics AG Reports Non-Inferiority of Blood-based Epi proColon® against Fecal Immunochemical Testing in Detection of Colorectal Cancer in a Head-to-Head Comparative Study

PDF 85 KB   Berlin, Germany, December 04, 2012 – Epigenomics AG (ISIN: DE000A1K0516) announces top-line results from a head-to-head comparative study between its blood-based colorectal cancer (CRC) detection test Epi proColon® and fecal immunochemical testing (FIT) to demonstrate the non-inferiority of Epi proColon® in detection of CRC. In the reported trial, Epi proColon® detected […]

Read more

Ad hoc: Epigenomics AG announces changes in its Executive Management Board

PDF 85 KB   Berlin, Germany, September 25, 2012 – The Supervisory Board of Epigenomics AG (ISIN: DE000A1K0516) and its current CEO Geert Walter Nygaard today agreed that Mr. Nygaard will leave the Executive Management Board of the company effective 30 September 2012. The current CFO, Dr. Thomas Taapken, thereby becomes the sole Executive Board […]

Read more

Ad hoc: Epigenomics AG Plans Changes in the Composition and Size of its Supervisory Board

PDF 158 KB   Berlin, Germany – Epigenomics AG (ISIN: DE000A1K0516) today decided to propose to the shareholders of the company at the upcoming Annual General Meeting on May 2, 2012 to vote in favor of a reduction of the size of the Supervisory Board from currently six to three members. Furthermore, the company’s Chairman, […]

Read more

Epigenomics AG Completes U.S. Clinical Validation Study for Colorectal Cancer Blood Test Epi proColon; Provides Update on U.S. Regulatory Plans

PDF 79 KB   Berlin, Germany Epigenomics AG (ISIN: DE000A1K0516) reports the completion of the clinical validation study for its second-generation colorectal cancer blood test Epi proColon in the U.S. The study was designed to measure the clinical performance of Epi proColon for the detection of colorectal cancer in comparison to colonoscopy and is part […]

Read more

Epigenomics AG Announces Restructuring of U.S. and European Operations

PDF 86 KB   Berlin, Germany, and Seattle, WA, U.S.A., August 10, 2011 Epigenomics AG (ISIN: DE000A1K0516) today released plans to restructure its organization and heighten the focus of its activities on the key U.S. market. Operations at the Epigenomics AG headquarters in Berlin, Germany, as well as at its subsidiary Epigenomics Inc. in Seattle, […]

Read more